Antibodies against PrP have been proposed as a valid therapeutic strategy against prion diseases, much like antibodies targeting the amyloid-β protein are showing promise in clinical trials against Alzheimer’s disease (AD) [8,9]. This evidence concerns the gene PRNP and Alzheimer disease.